División de Investigación, Hospital Juárez de México, Mexico City 07760, Mexico.
Hospital Nacional Homeopático, Hospitales Federales de Referencia, Mexico City 06800, Mexico.
Int J Mol Sci. 2022 Sep 4;23(17):10136. doi: 10.3390/ijms231710136.
Alzheimer's disease (AD) is the most common neurodegenerative disorder and its prevalence is increasing. Nowadays, very few drugs effectively reduce AD symptoms and thus, a better understanding of its pathophysiology is vital to design new effective schemes. Presymptomatic neuronal damage caused by the accumulation of Amyloid β peptide and Tau protein abnormalities remains a challenge, despite recent efforts in drug development. Importantly, therapeutic targets, biomarkers, and diagnostic techniques have emerged to detect and treat AD. Of note, the compromised blood-brain barrier (BBB) and peripheral inflammation in AD are becoming more evident, being harmful factors that contribute to the development of the disease. Perspectives from different pre-clinical and clinical studies link peripheral inflammation with the onset and progression of AD. This review aims to analyze the main factors and the contribution of impaired BBB in AD development. Additionally, we describe the potential therapeutic strategies using stem cells for AD treatment.
阿尔茨海默病(AD)是最常见的神经退行性疾病,其患病率正在增加。如今,很少有药物能有效减轻 AD 症状,因此,深入了解其病理生理学对于设计新的有效方案至关重要。尽管最近在药物开发方面做出了努力,但由淀粉样 β 肽和 Tau 蛋白异常积累引起的无症状神经元损伤仍然是一个挑战。重要的是,治疗靶点、生物标志物和诊断技术已经出现,以检测和治疗 AD。值得注意的是,AD 中受损的血脑屏障(BBB)和外周炎症变得更加明显,是导致疾病发展的有害因素。来自不同临床前和临床研究的观点将外周炎症与 AD 的发病和进展联系起来。本综述旨在分析 AD 发展中主要因素和受损 BBB 的贡献。此外,我们还描述了使用干细胞治疗 AD 的潜在治疗策略。